HATTRICK-OCT: biodegradable polymer struts coverage versus permanent

Late endothelialization of first generation pharmacological stents may predispose thrombosis. Both the drug and the polymer of the platform may affect the rate at which this occurs. This is a prospective, multicenter study which randomized 44 patients with acute coronary syndrome to receive sirolimus-eluting stent with bio-absorbable polymer versus zotarolimus-eluting stent with permanent polymer. The coating of the struts was assessed by OCT and the vasodilator response using CFR. 

There were no differences in clinical characteristics of patients but there was a significant difference in favor of the stent with bio-absorbable polymer in the number of struts not covered by OCT, (189/3.9% versus 495/8.9%, p <0.001), as well as in the amount of badly placed struts, (292/5.3 126/2.6% versus %, p <0.001). 

Conclusion: The sirolimus-eluting stent with bio-absorbable polymer showed better covered struts by endothelium after three months of angioplasty compared with the zotarolimus eluting stent with permanent polymer.

tuomas_kiviniemi_europcr
Tuomas Kiviniemi
2013-05-22

Original title: Early vascular healing of hybrid sirolimus-eluting stents with bioabsorbable polymer versus zotarolimus-eluting stents with durable polymer – HATTRICK-OCT Trial. 

More articles by this author

REPRISE II: results obtained with the new valve according to VARC criteria

The objective was to evaluate the safety and efficacy of the Lotus Valve System to treat patients with severe aortic stenosis and high surgical...

DEFLECT I: cerebral protection device in TAVI

Strokes after TAVI occur in between 3.8 and 6.7% of the cases, with new MRI lesions being almost the rule. The TriGuard EDD device...

DISCOVER: new low profile valve with little post-implant regurgitation

The objective of the study was to assess events after 30 days with the DirectFLOW Medical Valve device in patients with severe aortic stenosis...

JUPITER: transapical TAVI device

We evaluated 88 consecutive patients (at this phase) with severe aortic stenosis who received the second-generation device for transapical access. Survival at thirty days...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TAVR in Small Annuli: What Valve Should We Use?

One of the major challenges of severe aortic stenosis are patients with small aortic annuli, defined as ≤430 mm² aortic valve area. This condition...

Patients at High Risk of Bleeding After Coronary Angioplasty: Are Risk Assessment Tools ARC-HBR and PRECISE-DAPT Useful?

Patients undergoing coronary stenting typically receive dual antiplatelet therapy (DAPT) for 6 to 12 months, consisting of a P2Y12 receptor inhibitor and aspirin. While DAPT...

ACC 2025 | WARRIOR: Ischemia in Women with Non-Obstructive Coronary Artery Disease

Approximately half of all women with symptomatic ischemia who undergo coronary angiography are found to have non-obstructive coronary artery disease ((ischemia and non-obstructive coronary...